Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.38) by 92.11 percent. This is a 90.91 percent increase over losses of $(0.33) per share from the same period last year. The company reported $14.189 million in sales this quarter. This is a 39.15 percent increase over sales of $10.197 million the same period last year.